## BSX: Boston Scientific Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.94 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: declining volume (44% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($92.52)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Boston Scientific Corp. stock: quiet tape, loud expectations as Wall Street leans bullish**
- Source: AD HOC NEWS | 20251229T190842 | Bullish | Relevance: 100%
- Boston Scientific Corp. stock has remained in a narrow range recently, showcasing a high-conviction growth story in minimally invasive medicine, even as it trades near record highs. Despite recent minor pullbacks, analysts maintain a strong bullish outlook due to the company's robust innovation pipeline and strategic focus on high-growth segments in cardiovascular and neuromodulation therapies. Investors are watching for continued procedure growth and effective integration of acquisitions to further propel the stock.

**2. Boston Scientific Corp. stock: quiet tape, loud expectations as Wall Street leans bullish**
- Source: AD HOC NEWS | 20251229T190805 | Bullish | Relevance: 100%
- Boston Scientific Corp. stock has shown subdued price action recently but is backed by a strong growth story in minimally invasive medicine and positive analyst calls. While current valuations are high, the company benefits from a deep innovation pipeline, particularly in cardiovascular and neuromodulation franchises, and stabilizing medtech sector trends. Wall Street remains largely bullish, expecting the stock's current consolidation to be a pause before further gains.

**3. Sowell Financial Services LLC Sells 28,806 Shares of Boston Scientific Corporation $BSX**
- Source: MarketBeat | 20251229T110025 | Neutral | Relevance: 100%
- Sowell Financial Services LLC significantly reduced its stake in Boston Scientific Corporation by selling 28,806 shares in Q3, now owning 27,546 shares valued at approximately $2.69 million. Despite this, Boston Scientific exceeded Q3 earnings and revenue estimates and set strong FY2025 guidance. The company maintains high institutional ownership and a consensus "Buy" rating from analysts with an average target price of $124.85.

**4. Boston Scientific Corporation $BSX Stock Position Lessened by Ethic Inc.**
- Source: MarketBeat | 20251229T095159 | Neutral | Relevance: 100%
- Ethic Inc. reduced its stake in Boston Scientific Corporation by 10.7% in the third quarter, while other institutional investors have shown varied activity, some increasing their holdings. Boston Scientific reported strong Q3 earnings, surpassing analyst estimates with $0.75 EPS and revenues of $5.07 billion, and provided optimistic guidance for FY2025. Despite this, company insiders, including two EVPs, have been net sellers of the stock in the last 90 days.

**5. BSX vs. RMD: Which Medical Device Stock Is the Stronger Play Now?**
- Source: The Globe and Mail | 20251230T140833 | Somewhat-Bullish | Relevance: 95%
- This article compares two medical device giants, Boston Scientific (BSX) and Resmed (RMD), evaluating their market positions, growth strategies, and financial outlook. While both companies show promising prospects and strong analyst ratings, Boston Scientific is highlighted as a more attractive option due to its current price performance and diversified growth streams, carrying a Zacks Rank #2 (Buy) compared to Resmed's #3 (Hold). The article details each company's recent achievements, product innovations, and market expansion efforts.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Truist Securiti | $120 | $130 | -8% |
| 2025-12-17 | Canaccord Genui | $131 | $132 | -1% |
| 2025-12-17 | RBC Capital | $130 | $125 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Truist Securiti | main | Buy |
| 2025-12-17 | Canaccord Genui | main | Buy |
| 2025-12-17 | RBC Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 3 ($1.31M) |
| Sells | 8 ($2.57M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 9.8% (-1.0%)
- Vanguard Group Inc: 9.3% (+0.8%)
- FMR, LLC: 6.7% (-8.2%)
- State Street Corpora: 4.4% (-0.4%)
- JPMORGAN CHASE & CO: 3.8% (+120.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_20 improving +1.9% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.94 indicates undervaluation relative to growth. Balance sheet: $2.6B free cash flow. Analyst sentiment negative (2 target cuts vs 1 raises). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $142.3B |
| Beta | 0.67 |
| 52W Range | $85.98 - $109.50 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.94 |
| Forward P/E | 27.7 |
| Current P/E | 31.6 |
| YoY Growth | 14.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -1.2% to 0.7% (+1.9% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.3pp (needs >4.0% for momentum thesis). MRS_5 at 0.5% confirms short-term momentum alignment. Below SMA200 (0.95x), long-term trend not supportive. RSI neutral at 48. Volume at 44% of 20MA suggests lack of conviction. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.70% (CS: 61) | Neutral |
| RSI_14 | 48.3 | Neutral |
| MACD Histogram | 0.37 | Bullish |
| vs SMA20 | 1.008x | Above |
| vs SMA50 | 0.975x | Below |
| vs SMA200 | 0.951x | Below |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $96.00
- **Stop Loss:** $92.52 (3.6% risk)
- **Target:** $102.96 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 379
- **Position Value:** $36,384.00
- **Portfolio %:** 36.38%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-02-04 (Est: $0.78)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.71 | $0.75 | +5.1% |
| 2025Q2 | $0.73 | $0.75 | +3.4% |
| 2025Q1 | $0.67 | $0.75 | +11.5% |
| 2024Q4 | $0.66 | $0.70 | +6.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*